These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 2498754

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Acute clonidine administration potentiates spontaneous diurnal, but not nocturnal, growth hormone secretion in normal short children.
    Ghigo E, Arvat E, Nicolosi M, Bellone J, Valetto MR, Mazza E, Imperiale E, Procopio M, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Aug; 71(2):433-5. PubMed ID: 2380338
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children.
    Ghigo E, Mazza E, Corrias A, Imperiale E, Goffi S, Arvat E, Bellone J, De Sanctis C, Müller EE, Camanni F.
    Metabolism; 1989 Jul; 38(7):631-3. PubMed ID: 2500577
    [Abstract] [Full Text] [Related]

  • 7. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A, Muruais C, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [Abstract] [Full Text] [Related]

  • 8. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 9. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Growth hormone secretion in aging. Effect of pyridostigmine on growth hormone responsiveness to growth hormone-releasing hormone.
    Giusti M, Marini G, Sessarego P, Peluffo F, Valenti S, Caratti C, Giordano G.
    Recenti Prog Med; 1991 Dec; 82(12):665-8. PubMed ID: 1815302
    [Abstract] [Full Text] [Related]

  • 13. Evidence for involvement of endogenous somatostatin in the galanin-induced growth hormone secretion in children.
    Loche S, Vista N, Ghigo E, Vannelli S, Arvat E, Benso L, Corda R, Cella SG, Müller EE, Pintor C.
    Pediatr Res; 1990 Apr; 27(4 Pt 1):405-7. PubMed ID: 1692988
    [Abstract] [Full Text] [Related]

  • 14. Somatostatinergic tone in children on chronic haemodialysis and after renal transplantation.
    Cappa M, del Balzo P, Rizzoni G, Benedetti S, Borrelli P.
    Pediatr Nephrol; 1991 Jul; 5(4):548-51. PubMed ID: 1680365
    [Abstract] [Full Text] [Related]

  • 15. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
    [Abstract] [Full Text] [Related]

  • 16. Effects of pyridostigmine on spontaneous and growth hormone-releasing hormone stimulated growth hormone secretion in children on daily glucocorticoid therapy after liver transplantation.
    Giustina A, Girelli A, Alberti D, Bossoni S, Buzi F, Doga M, Schettino M, Wehrenberg WB.
    Clin Endocrinol (Oxf); 1991 Dec; 35(6):491-8. PubMed ID: 1769130
    [Abstract] [Full Text] [Related]

  • 17. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E, Imperiale E, Boffano GM, Mazza E, Bellone J, Arvat E, Procopio M, Goffi S, Barreca A, Chiabotto P.
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [Abstract] [Full Text] [Related]

  • 18. Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children.
    Ghigo E, Bellone J, Imperiale E, Arvat E, Mazza E, Valetto MR, Boffano GM, Cappa M, Loche S, De Sanctis C.
    Neuroendocrinology; 1990 Jul; 52(1):42-5. PubMed ID: 1697660
    [Abstract] [Full Text] [Related]

  • 19. Pyridostigmine does not reverse dexamethasone-induced growth hormone inhibition.
    del Balzo P, Salvatori R, Cappa M, Gertner JM.
    Clin Endocrinol (Oxf); 1990 Nov; 33(5):605-12. PubMed ID: 1979261
    [Abstract] [Full Text] [Related]

  • 20. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R, Valente F, Dieguez C, Zini M, Procopio M, Portioli I, Ghigo E.
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.